請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18861
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林文貞(Wen-Jen Lin) | |
dc.contributor.author | Shu-An Lee | en |
dc.contributor.author | 李曙安 | zh_TW |
dc.date.accessioned | 2021-06-08T01:37:59Z | - |
dc.date.copyright | 2017-02-24 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-11-29 | |
dc.identifier.citation | Aiedeh K and Taha MO. Synthesis of iron-crosslinked chitosan succinate and iron-crosslinked hydroxamated chitosan succinate and their in vitro evaluation as potential matrix materials for oral theophylline sustained-release beads. Eur J Pharm Sci. 2001;13(2):159-168.
Amiri FS. Contemporary management of phosphorus retention in chronic kidney disease: a review. Clin Exp Nephrol. 2015;19(6):985-999. Arami S, Rashidi MR, Mahdavi M, Fathi M and Entezami AA. Synthesis and characterization of Fe3O4-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system. Hum Exp Toxicol. 2016;1-11. Baxter J, Shimizu F, Takiguchi Y, Wada M and Yamaguchi T. Effect of iron(III) chitosan intake on the reduction of serum phosphorus in rats. J Pharm Pharmacol. 2000;52(7):863-874. Beckers EJ, Rehrer NJ, Brouns F, Ten Hoor F and Saris WH. Determination of total gastric volume, gastric secretion and residual meal using the double sampling technique of George. 1998;29(12):1725-1729. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al. Effects of Phosphate Binders in Moderate CKD. J Am Soc Nephrol. 2012;23(8):1407-1415. Borsagli FGLM, Mansur AAP, Chagas P, Oliveira LCA and Mansur HS. O-carboxymethyl functionalization of chitosan: Complexation and adsorption of Cd (II) and Cr (VI) as heavy metal pollutant ions. React Funct Polym. 2015;97:37-47. Burger C, Valcarenghi D, Sandri S and Rodrigues CA. Cross-linking chitosan-Fe(III), an oral phosphate binder: studies in vitro and in vivo. Int J Pharm. 2001;223(1-2):29-33. Burtis CA, Ashwood ER and Bruns ED. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th ed. St. Louis (MO): Saunders Elsevier. 2006;1891-1965. Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, et al. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renov. 2016;9:11-19. Chae SY, Jang MK and Nah JW. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release. 2005;102(2):383-394. Chang SH, Lin HTV, Wu GJ and Tsai GJ. pH Effects on solubility, zeta potential, and correlation between antibacterial activity and molecular weight of chitosan. Carbohyd Polym. 2015;134:74-81. Chen JB, Chiang SS, Chen HC, Obayashi S, Nagasawa M, Hexham JM, et al. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology. 2011;16(8):743-750. Chen PS, Toribara TY and Warner H. Microdetermination of Phosphorus. Anal Chem. 1956;28(11):1756-1758. Corazzari I, Nistico R, Turci F, Faga MG, Franzoso F, Tabasso S and Magnacca G. Advanced physico-chemical characterization of chitosan by means of TGA coupled on-line with FTIR and GCMS: Thermal degradation and water adsorption capacity. Polymer Degradation and Stability. 2015;112:1-9. Croisier F and Jerome C. Chitosan-based biomaterials for tissue engineering. Eur Polym J. 2013;49(4):780-792. Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M and Bolasco P. Phosphate control in dialysis. Int J Nephrol Renovasc Dis. 2013;6:193-205. de Cuadro P, Belt T, Kontturi KS, Reza M, Kontturi E, Vuorinen T, et al. Cross-linking of cellulose and poly(ethylene glycol) with citric acid. React Funct Polym. 2015;90:21-24. de Jong G, van Dijk JP and van Eijk HG. The biology of transferrin. Clin Chim Acta. 1990;190:1-46. de Sousa AF, Braga TP, Gomes ECC, Valentini A and Longhinotti E. Adsorption of phosphate using mesoporous spheres containing iron and aluminum oxide. Chem Eng J. 2012;210:143-149. El-Sherbiny IM and El-Baz NM. A Review on Bionanocomposites Based on Chitosan and Its Derivatives for Biomedical Applications. Eco-friendly Polymer Nanocomposites. 2015;74:173-208. Floege J, Covic AC, Ketteler M, Rastogi A, Chong EMF, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638-647. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol. 2016;29(3):329-340. Geisser P and Philipp E. Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent. U.S. Patent 6174442. 2004. Ghaz-Jahanian MA, Abbaspour-Aghdam F, Anarjan N, Berenjian A and Jafarizadeh-Malmiri H. Application of Chitosan-Based Nanocarriers in Tumor-Targeted Drug Delivery. Mol Biotechnol. 2015;57(3):201-218. Harhay MN, Harhay MO, Coto-Yglesias F and Bixby LR. Altitude and regional gradients in chronic kidney disease prevalence in Costa Rica: Data from the Costa Rican Longevity and Healthy Aging Study. Trop Med Int Health. 2016;21(1):41-51. Hebeish A, Elnagar Kh, Helal MH, Ragab MS, Shaaban MF. UV/O3 Preirradiated Cotton Fabric-Containing Chitosan for Effective Removal of Heavy Metals. Materials Sciences and Applications. 2014;5(10):698-707. Hejazi R and Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151-165. Henry RJ, Cannon DC and Winkelman WJ. Clinical chemistry : principles and technics, 2nd ed. New York, NY: Harper & Row. 1974;723. Holick MF. Vitamin D deficiency. New Engl J Med. 2007;357(3):266-281. Hsu CH, Patel SR and Young EW. New phosphate binding agents: Ferric compounds. J Am Soc Nephrol. 1999;10(6):1274-1280. Hutchison AJ, Wilson RJ, Garafola S and Copley J. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton). 2016. Iimori S, Mori Y, Akita W, Takada S, Kuyama T, Ohnishi T, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol. 2012;16(6):930-937. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2014;63(5):713-735. Keimirov MA. Sorbents with the structure of layered double hydroxides for aquatic media treatment from U(VI). J Water Chem Techno+. 2016;38(3):128-133. Ketteler M, Wuthrich RP and Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J. 2013;6(2):128-136. King J. Oral iron (iii) based phosphate adsorbent for treating iron-deficiency anemia in cats with chronic kidney disease. U.S. Patent 20150313939. 2015. Kubota N, Tatsumoto N, Sano T and Toya K. A simple preparation of half N-acetylated chitosan highly soluble in water and aqueous organic solvents. Carbohyd Res. 2000;324(4):268-274. Kurita K. Controlled functionalization of the polysaccharide chitin. Progress in Polymer Science. 2001;26(9):1921-1971. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, et al. Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. J Am Soc Nephrol. 2015;26(2):493-503. Li W, McIntyre TM and Silverstein RL. Ferric chloride-induced murine carotid arterial injury: A model of redox pathology. Redox Biol. 2013;1(1):50-55. Liao XP, Ding Y, Wang B and Shi B. Adsorption behavior of phosphate on metal-ions-loaded collagen fiber. Ind Eng Chem Res. 2006;45(11):3896-3901. Liu L, Wang H, Liu Q, Duan M, Dong X, Zhu D, et al. Biodistribution of TAT-LHRH conjugated chitosan/DNA nanoparticles in the mice bearing hepatoma xenografts. J Biomed Mater Res A. 2016;104(10):2394-2400. Liu Q, Hu P, Wang J, Zhang LJ and Huang RH. Phosphate adsorption from aqueous solutions by Zirconium (IV) loaded cross-linked chitosan particles. J Taiwan Inst Chem E. 2016;59:311-319. Liu Y, Shena X, Zhoua H, Wangc Y and Denga L. Chemical modification of chitosan film via surface grafting of citric acid molecular to promote the biomineralization. Applied Surface Science. 2016;370(1):270-280. Lu SJ, Song XF, Cao DY, Chen YP and Yao KD. Preparation of water-soluble chitosan. J Appl Polym Sci. 2004;91(6):3497-3503. Ly HTY, Tong NX, Tan LV. Adsorption thermodynamic and kinetic studies of Cr(VI) by chitosan flake modified with citric acid via crosslinking with glutaraldehyde. Vietnam Journal of Chemistry. 2016;52(2):159-164. Mao SR, Shuai XT, Unger F, Simon M, Bi DZ and Kissel T. The depolymerization of chitosan: effects on physicochemical and biological properties. Int J Pharm. 2004;281(1-2):45-54. Martin P, Wang P, Robinson A, Poole L, Dragone J and Smyth M. Comparison of Dietary Phosphate Absorption After Single Doses of Lanthanum Carbonate and Sevelamer Carbonate in Healthy Volunteers: A Balance Study. Am J Kidney Dis. 2011;57(5):700-706. McIntyre CW, Pai P, Warwick G, Wilkie M, Toft AJ and Hutchison AJ. Iron-Magnesium Hydroxycarbonate (Fermagate): A Novel Non-Calcium-Containing Phosphate Binder for the Treatment of Hyperphosphatemia in Chronic Hemodialysis Patients. Clin J Am Soc Nephro. 2009;4(2):401-409. Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. 2014;11(9):3039-3047. Muzzarelli RAA. Chitins and chitosans for the repair of wounded skin, nerve, cartilage and bone. Carbohyd Polym. 2009;76(2):167-182. Nastou D, Fernandez-Fernandez B, Elewa U, Gonzalez-Espinoza L, Gonzalez-Parra E, Sanchez-Nino MD, et al. Next-Generation Phosphate Binders: Focus on Iron-Based Binders. Drugs. 2014;74(8):863-877. Nguyen TMH, Muller RH, Taupitz M, Schnorr J, Hamm B and Wagner S. Novel oral phosphate binder with nanocrystalline maghemite-phosphate binding capacity and pH effect. Int J Pharm. 2015;482(1-2):21-26. Nolan CR. Phosphate binder therapy for attainment of K/DOQI (TM) bone metabolism guidelines. Kidney Int. 2005;68:S7-S14. Pai AB, Jang SM and Wegrzyn N. Iron-based phosphate binders-a new element in management of hyperphosphatemia. Expert Opin Drug Metab Toxicol. 2016;12(1):115-127. Panith N, Wichaphon J, Lertsiri S and Niamsiri N. Effect of physical and physicochemical characteristics of chitosan on fat-binding capacities under in vitro gastrointestinal conditions. Lwt-Food Sci Technol. 2016;71:25-32. Phan O, Maillard M, Malluche HH, Stehle JC, Funk F and Burnier M. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. Biomed Research International. 2015:1-9. Phan O, Maillard M, Peregaux C, Mordasini D, Stehle JC, Funk F, and Burnier M. PA21, a New Iron-Based Noncalcium Phosphate Binder, Prevents Vascular Calcification in Chronic Renal Failure Rats. J Pharmacol Exp Ther. 2013;346(2):281-289. Repo E, Warchol JK, Kurniawan TA and Sillanpaa MET. Adsorption of Co(II) and Ni(II) by EDTA- and/or DTPA-modified chitosan: Kinetic and equilibrium modeling. Chem Eng J. 2010;161(1-2):73-82. Ritz E, Hahn K, Ketteler M, Kuhlmann MK and Mann J. Phosphate Additives in Food-a Health Risk. Dtsch Arztebl Int. 2012;109(4):49-U29. Salgin S, Salgin U and Bahadir S. Zeta Potentials and Isoelectric Points of Biomolecules: The Effects of Ion Types and Ionic Strengths. Int J Electrochem Sci. 2012;7:12404-12414. Schmid H and Lederer SR. Novel iron-containing phosphate binders for treatment of hyperphosphatemia. Expert Opin Pharmaco. 2015;16(14):2179-2191. Shaman AM and Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi Pharm J. 2016;24(4):494-505. Shen C, Shen Y, Wen Y, Wang H, Liu W. Fast and highly efficient removal of dyes under alkaline conditions using magnetic chitosan-Fe(III) hydrogel. Water research. 2011;45:5200-5210. Siedel J, Wahlefeld AW, Ziegenhorn J. A new iron ferrozine reagent without deproteinization. Clin Chem. 1984;30:975. Silva JM, Georgi N, Costa R, Sher P, Reis RL, Van Blitterswijk CA, et al. Nanostructured 3D Constructs Based on Chitosan and Chondroitin Sulphate Multilayers for Cartilage Tissue Engineering. Plos One. 2013;8(2):1-11. Soccol CR, Vandenberghe LPS, Rodrigues C and Pandey A. New perspectives for citric acid production and application. Food Technol Biotech. 2006;44(2):141-149. Song HJ, Su C, Cui WY, Zhu BY, Liu LW, Chen ZH, et al. Folic Acid-Chitosan Conjugated Nanoparticles for Improving Tumor-Targeted Drug Delivery. Biomed Research International. 2013:1-6. Stephen-Haynes J, Gibson E and Greenwood M. Chitosan: a natural solution for wound healing. JCN. 2014;28(1):48-54. Suc NV and Ly HTY. Lead (II) removal from aqueous solution by chitosan flake modified with citric acid via crosslinking with glutaraldehyde. 2013;88:1641-1649. Sureshkumar V, Daniel SCGK , Ruckmani K and Sivakumar M. Fabrication of chitosan–magnetite nanocomposite strip for chromium removal. Appl Nanosci. 2016;6(2):277–285 Tomida H, Fujii T, Furutani N, Michihara A, Yasufuku T, Akasaki K, et al. Antioxidant properties of some different molecular weight chitosans. Carbohyd Res. 2009;344(13):1690-1696. Van Camp YPM, Vrijens B, Abraham I, Van Rompaey B and Elseviers M. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. Journal of Nephrology. 2014;27(6):673-679. van der Gronde T, Hartog A, van Hees C, Pellikaan H and Pieters T. Systematic review of the mechanisms and evidence behind the hypocholesterolaemic effects of HPMC, pectin and chitosan in animal trials. Food Chemistry. 2016;199:746-759. Varma AJ, Deshpande SV and Kennedy JF. Metal complexation by chitosan and its derivatives: a review. Carbohyd Polym. 2004;55(1):77-93. Wang JL and Chen C. Chitosan-based biosorbents: Modification and application for biosorption of heavy metals and radionuclides. Bioresource Technol. 2014;160:129-141. Wen Y, Ma J, Chen J, Shen C, Li H and Liu W. Carbonaceous sulfur-containing chitosan–Fe(III): A novel adsorbent for efficient removal of copper (II) from water. Chemical Engineering Journal. 2015;259(1):372-380. Wick M, Pinggera W and Lehmann P. Eisenstoffwechsel, Diagnostik und Therapie der Anämien, 3rd ed. Wien/New York: Springer Verlag. 1996. Wilhelm M, Gaillard S, Rakov V and Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(4):251-258. Wu J, Jiang W, Tian R, Shen Y and Jiang W. Facile synthesis of magnetic-/pH-responsive hydrogel beads based on Fe3O4 nanoparticles and chitosan hydrogel as MTX carriers for controlled drug release. Journal of Biomaterials Science, Polymer Edition. 2016;27(15):1-32. Xia G, Lang X, Kong M, Cheng X, Liu Y, Feng C, et al. Surface fluid-swellable chitosan fiber as the wound dressing material. Carbohydr Polym. 2016;136:860-866. Xie ZW, Aphale NV, Kadapure TD, Wadajkar AS, Orr S, Gyawali D, et al. Design of antimicrobial peptides conjugated biodegradable citric acid derived hydrogels for wound healing. Journal of Biomedical Materials Research Part A. 2015;103(12):3907-3918. Xing RE, Liu S, Guo ZY, Yu HH, Wang PB, Li CP, et al. Relevance of molecular weight of chitosan and its derivatives and their antioxidant activities in vitro. Bioorgan Med Chem. 2005;13(5):1573-1577. Yang Y, Yuan SX, Zhao LH, Wang C, Ni JS, Wang ZG, et al. Ligand-Directed Stearic Acid Grafted Chitosan Micelles to Increase Therapeutic Efficacy in Hepatic Cancer. Mol Pharmaceut. 2015;12(2):644-652. Yang YS, Mohammad A, Berendt RT, Carlin A, Khan MA and Faustino PJ. Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate. J Pharm Sci-Us. 2016;105(2):864-875. Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl. 2014;29(5):1053-1060. Yong SK, Bolan NS, Lombi E, Skinner W and Guibal E. Sulfur-Containing Chitin and Chitosan Derivatives as Trace Metal Adsorbents: A Review. Crit Rev Env Sci Tec. 2013;43(16):1741-1794. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research. 2002;19(7):921-925. Zhang CL, Wen J, Li Z and Fan JM. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. Bmc Nephrol. 2013;14:1-14. Zheng L, Wang C, Shu Y, Yan X and Li L. Utilization of diatomite/chitosan–Fe (III) composite for the removal of anionic azo dyes from wastewater: Equilibrium, kinetics and thermodynamics. Colloids and Surfaces A: Physicochem. Eng Aspects. 2015;468(5):129-139. 許志成, 熊昭, 陳鴻鈞, 黃秋錦, 黃尚志, 吳麥斯, 簡麗年, 林彥仲, 高治圻等. 台灣腎病年報. 2015. 陳姿丹. 複合式接枝型幾丁聚醣之合成與研究. 2008. 黃文德, 朱柏齡, 許育瑞.磷結合劑在慢性腎臟疾病病人運用的新進展. 內科學誌. 2014;25:184-194. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18861 | - |
dc.description.abstract | 慢性腎臟衰竭的病患通常需要搭配血液透析進行治療,血液透析後常常會伴隨著高血磷的副作用,高血磷會增加心血管併發症的致死率,故需要服用降血磷的藥物,而目前臨床上所使用的口服降血磷藥物仍然有許多缺點,最主要的缺點為藥物效價不佳,患者需要每天服用大劑量的藥物,使得病患的用藥順從性變差。新一代口服降血磷藥物以鐵作為吸附磷的活性成分,吸附胃腸道中的磷來達到降血磷的效果,雖然結果顯示新一代含鐵藥物可以達到和目前藥物相同的降血磷效果,但每天需要給予大劑量這個缺點仍然沒有克服。
本實驗選擇了幾丁聚醣當作主體,藉由幾丁聚醣的低毒性和可以結合金屬之特性,且結構上也與臨床的降血磷藥物Sevelamer相近,除此之外藉由接枝上自然界常見且毒性低的三元酸-檸檬酸,利用檸檬酸上的羧基,希望藉此增加化合物的鐵含量並加強降血磷的效果。本研究合成的部分主要分為兩個階段,第一階段為合成不同去乙醯化度的去聚合幾丁聚醣並與檸檬酸進行接枝反應,藉由去聚合和改變不同去乙醯化度來增加化合物的水溶性,並嘗試提高檸檬酸的接枝率,第二階段再利用上述合成的不同去乙醯化度之檸檬酸接枝型幾丁聚醣來與鐵進行結合。第一階段的去乙醯化度和檸檬酸接枝率利用紅外線分光光譜儀(ATR)和核磁共振光譜儀(NMR)進行確認,並使用膠體滲透層析(GPC)確認樣品的分子量和檸檬酸接枝的方式,並且利用紫外光/可見光分光光譜儀(UV/visible spectrophotometer)測量不同樣品在水中的穿透度比較各樣品的溶解度。第二階段進行鐵接合反應,樣品鐵含量測定是利用硫氰酸根(SCN-)和鐵結合後會形成紅色的複合物,此複合物在波長480 nm會有最大吸收,以鐵之檢量線進行樣品的鐵含量檢測。 製備好的樣品分別以體外和體內(in vitro and in vivo study)進行磷吸附試驗和鐵釋放試驗,體外試驗以pH 1.0、4.5和 7.5,在三種不同環境中2小時來測試樣品的磷吸附效果,並檢測樣品鐵釋放的情形,除了固定的pH環境外,也模擬了胃腸道中pH變化的環境,分別在pH 1.0,1小時、pH 4.5,1.5小時和pH 7.5,4.5小時,階段性pH變化之磷吸附試驗,樣品的磷含量測定是利用了鉬酸根離子(MoO42-)和磷結合後會形成藍綠色的複合物,此複合物在波長820 nm有最大吸收,以磷的檢量線進行樣品的磷含量檢測。體內試驗則是使用了10-15週齡的Wistar大鼠,將合成含鐵的樣品以固定比例0.25% w/w混入大鼠的飼料進行給藥,並且以臨床上常使用的口服降血磷藥物-碳酸鈣(CaCO3),給予相同的劑量當作對照組,每週抽血確認大鼠的血磷,並監測血鈣、血鐵、體重、外觀變化、食慾和活動力。 樣品合成的實驗結果顯示,不同去乙醯化度的接枝型檸檬酸去聚合幾丁聚醣,去乙醯化度分別為100%、75%、60%和40%,檸檬酸接枝率為20.5-30.5%,重量分子量(Mw)介於8,000-11,000 Da,第二階段的鐵接合反應,結果發現檸檬酸接枝型去聚合幾丁聚醣,每克樣品可接上270-315 mg鐵,比起不含有檸檬酸基的樣品,每克樣品只能接140-170 mg鐵,上升了67-110%,統計上具有顯著差異,證實了檸檬酸基可以增加樣品之含鐵量。 體外的磷吸附試驗結果顯示,在pH 1.0的環境下2小時,不含鐵之樣品幾乎沒有吸附磷的效果,證實了鐵為吸附磷之關鍵角色,而不含檸檬酸基的含鐵樣品,每克樣品能夠吸附磷約265-290 mg,但若是接枝檸檬酸的含鐵樣品,吸附磷的量可以提升至每克樣品吸附366-389 mg,統計上有顯著差異,但在pH 4.5和7.5環境時,發現含鐵樣品會沉澱出來而形成懸浮液,此時樣品的磷吸附效果較差,每克樣品磷吸附量約為88-120 mg和106-119 mg,而模擬胃腸道環境階段性改變pH值的磷吸附試驗,測試結果發現經過長時間且階段性pH值改變後,各樣品吸附磷的量並沒有明顯的改變,顯示了樣品吸附上磷之後,並不會因環境pH值變化而減少了原本磷的吸附量。 動物試驗結果,給藥三週後血磷從5.82 mg/dL下降至5.09 mg/dL(碳酸鈣組)和4.84 mg/dL (樣品組),證實本實驗樣品具有較好的降血磷效果,血鈣則是從2.58 mmol/L上升至2.72 mmol/L (碳酸鈣組)和2.69 mmol/L (樣品組),兩組血鈣無顯著差異,但樣品組別上升情況較輕微,血鐵則是從49.26 μmol/L下降至35.07 μmol/L (碳酸鈣組)和40.66 μmol/L (樣品組),給予實驗樣品的組別血鐵降低的程度較小,而兩組體重、食慾、外觀和活動力並無顯著差異,證實碳酸鈣和樣品無明顯副作用和毒性,從排泄物觀察到給予樣品組別糞便有些許變深的情況,此現象也能夠推測樣品(深褐色)吸附磷之後並不會被腸胃道吸收,而是會從糞便中排出,藉此抑制腸胃道吸收磷的量。 | zh_TW |
dc.description.abstract | Patients with chronic kidney disease usually need to be treated with hemodialysis. Hemodialysis often accompanies with side effects of hyperphosphatemia. Hyperphosphatemia would increase the mortality of cardiovascular complications, so it is necessary to take phosphate binders. However, current clinical oral phosphate binders still have many disadvantages and the main one is poor potency. Patients need to take large doses of drugs daily, which would make patients’ compliance worse. A new generation of oral phosphate binders uses iron as the active ingredient to adsorb phosphate in the gastrointestinal tract to lower phosphorus level. Although the results show that the new generation of iron-based drugs can achieve the same effect as the current drugs, taking high daily doses is still not overcome.
In this study, chitosan was chosen as the main structure based on its low toxicity and the ability of combining with metals. Besides, the structure of chitosan is similar to Sevelamer, a clinical phosphate binder. In addition, this research utilized citric acid- a tribasic acid, which is common in the nature and low toxicity, to conjugate with chitosan. Due to the carboxyl group on citric acid, it is expected to increase the iron content of the sample and enhance the effect of lowering blood phosphorus. The synthesis of this study was divided into two parts. The first part was the synthesis of depolymerized chitosan with different deacetylation degree and the conjugation reaction with citric acid. The purpose of depolymerization and varying deacetylation degrees is to increase the water-solubility of samples and conjugation ratio of citric acid. In the second part, citric acid conjugated depolymerized chitosan with different deacetylation degree were used to crosslink with the iron. The deacetylation degree and citric acid conjugation ratio of first part were confirmed by infrared spectroscopy (ATR) and nuclear magnetic resonance spectroscopy (NMR). Besides, the molecular weight and the conjugation way of citric acid were confirmed by gel permeation chromatography (GPC). And the solubility of each sample was compared by measuring the transmittance in water by UV/visible spectrophotometer. The iron content of second part samples was determined by thiocyanate (SCN-) which would combine with iron and form a red complex. The complex had the maximum absorption at wavelength of 480 nm and the iron content of samples was measured by the calibration curve. The prepared samples were carried out the phosphate adsorption test and the iron release test in vitro and in vivo. In vitro study, the samples were tested at pH 1.0, 4.5 and 7.5 three different environments for 2 hours for the phosphate adsorption ability and the iron release ratio. In addition to the fixed pH environment, the staged pH change of the phosphate adsorption test simulated the conditions in the gastrointestinal tract at pH 1.0, 1 hour, pH 4.5, 1.5 hours and pH 7.5, 4.5 hours. The phosphate adsorption of samples was determined by molybdate (MoO42-) which would combine with phosphate and form a blue-green complex. The complex had the maximum absorption at wavelength of 820 nm and the phosphate absorption of samples was measured by the calibration curve. In vivo study, 10-15 weeks old Wistar rats were used. The iron-based samples were mixed into rats’ diet at the ratio of 0.25% w/w. And gave the same dose of calcium carbonate (CaCO3) which was an oral phosphate binder commonly used in clinical practices as the control group. Blood sampled every week to confirm the phosphorus level and monitor calcium, iron, body weight, appearance changes, appetite and activity. The synthesis results of citric acid conjugated depolymerized chitosan with different deacetylation degree were shown that the deacetylation degree was 100%, 75%, 60% and 40%, respectively, the conjugation ratio of citric acid was 20.5% to 30.5%, and the molecular weight (Mw) was 8,000 to 11,000 Da. In the second part of the iron-crosslinking reaction, it was found that the citric acid conjugated samples could bind 270-315 mg iron per gram. Compared to the samples without citric acid groups which could only bind 140-170 mg iron per gram, the iron content increased 67% to 110%. And the difference of two groups was statistically significant, which confirmed that the citric acid groups could increase the iron content. In vitro phosphate adsorption experiments results showed that there was almost no phosphate adsorption on iron-free samples at pH 1.0 for 2 hours, which confirmed that iron played an important role for phosphate adsorption. The citric acid-free and iron-based samples adsorbed about 265-290 mg phosphate per gram. On the other hand, the iron-based samples with citric acid groups, the amount of adsorbed phosphate could be increased to 366-389 mg per gram. And the difference of two groups was statistically significant. However, at pH 4.5 and 7.5, the samples would precipitate and form a suspension. At this time, the phosphate adsorption capacity of all samples was poor and the amount of phosphate adsorption was about 88-120 mg and 106-119 mg per gram. And the results of phosphate adsorption test in the condition of staged pH change showed that after a long period of time and pH change, the amount of phosphate adsorption of each sample did not change significantly. It showed that the amount of phosphate adsorption on the sample would not be reduced by changing the pH value. In vivo study results showed that the serum phosphorus decreased from 5.82 mg/dL to 5.09 mg/dL (calcium carbonate group) and 4.84 mg/dL (sample group) after three weeks administration. The results showed that samples had better effect on lowering serum phosphorus. The serum calcium increased from 2.58 mmol/L to 2.72 mmol/L (calcium carbonate group) and 2.69 mmol/L (sample group). There was no significant difference between the two groups, but the increase of the sample group was minor. The serum iron decreased from 49.26 μmol/L to 35.07 μmol/L (calcium carbonate group) and 40.66 μmol/L (sample group), and the reduction of the sample group was minor. Besides, there was no significant difference in body weight, appetite, appearance and activity between two groups. It was observed that the feces of the sample group were slightly darker. This phenomenon was able to be estimated that the samples were not absorbed by the gastrointestinal tract, but were excreted from the feces, which inhibits the absorption of phosphate in gastrointestinal tract. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T01:37:59Z (GMT). No. of bitstreams: 1 ntu-105-R03423007-1.pdf: 7088968 bytes, checksum: cb6642d525203cb6ac93aeb8f968733d (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員會審定書 II
致謝 III 中文摘要 IV 英文摘要 VI 目錄 IX 表目錄 XVI 圖目錄 XIX 第一章 緒論 1 一、 高血磷 1 (一) 病因 1 (二) 盛行率及病理機轉 2 二、 高血磷之治療 3 (一) 飲食控制 3 (二) 降血磷藥物 4 1. 含鈣元素之藥物 5 2. 含鎂元素之藥物 5 3. 聚合物類之藥物-Sevelamer 5 4. 含鑭元素之藥物 6 5. 含鋁元素之藥物 7 三、 新一代含鐵元素之口服降血磷藥物 7 (一) Iron-magnesium hydroxycarbonate 8 (二) SBR759 (Polymeric complex of iron (III)) 9 (三) 檸檬酸鐵(Ferric citrate) 10 (四) Sucroferric oxyhydroxide (PA21) 10 四、 幾丁聚醣(Chitosan, CS) 12 (一) 簡介 12 (二) 降血磷之應用 12 (三) 抗癌之應用 13 (四) 傷口之敷料 14 (五) 抗菌 14 (六) 抑制脂肪吸收 14 (七) 吸附重金屬 15 五、 氯化鐵(Ferric chloride) 16 (一) 簡介 16 (二) Chitosan-Fe(III)和Chitosan-magnetite (Fe3O4)之應用 16 六、 檸檬酸(Citric acid, CA) 18 (一) 簡介 18 (二) 檸檬酸與幾丁聚醣之應用 19 第二章 實驗動機與目的 20 第三章 實驗試劑與儀器 22 一、 藥品 22 二、 儀器 24 三、 材料 26 四、 藥品溶液與緩衝溶液製備 26 第四章 實驗方法 28 一、 不同去乙醯化度的去聚合幾丁聚醣之合成 30 (一) 去乙醯去聚合幾丁聚醣DADPCS合成 30 1. DACS合成(Kurita, 2001) 30 2. DADPCS合成(Mao et al., 2004) 31 (二) 去聚合幾丁聚醣DPCS之合成(Mao, et al., 2004) 33 (三) 去聚合乙醯化幾丁聚醣DPCS N-Ac之合成(Lu et al., 2004) 35 二、 不同去乙醯化度去聚合幾丁聚醣之檸檬酸接枝反應- DADPCS CA、DPCS CA和DPCS N-Ac CA之合成 (陳姿丹, 2008) 37 (一) 反應時間 38 (二) EDC或NHS(莫耳數)/CA(當量數)之比例 39 (三) CA (當量數) /NH2 (莫耳數)之比例 41 三、 鐵接枝-(接枝型檸檬酸)-不同去乙醯化度去聚合幾丁聚醣- DADPCS (CA) Fe、DPCS (CA) Fe和DPCS N-Ac (CA) Fe和之合成(Aiedeh et al., 2001, Burger et al., 2001) 43 四、 結構及物性測定 46 (一) 紅外線分光光譜儀(Attenuated Total Reflectance; ATR) 46 (二) 核磁共振光譜儀(NMR) 46 (三) 膠體滲透層析(GPC) 46 (四) 水溶性測試(Kubota et al., 2000) 47 (五) 等電點滴定試驗(Salgin et al., 2013) 48 (六) 示差掃描熱分析儀(DSC) 48 五、 定量分析 49 (一) 含鐵量測試 (Aiedeh, et al., 2001) 49 (二) 含磷量測試((Chen et al., 1956) modified by Dunham et al., 2005) 50 六、 CS CA Fe、DADPCS CA Fe、DPCS CA Fe和DPCS N-Ac CA Fe之磷吸附試驗與釋放鐵量試驗 51 (一) pH 1.0、4.5和7.5之磷吸附試驗與釋放鐵量試驗(Burger et al., 2001) 51 (二) 模擬胃腸道從pH 1.0、4.5至7.5連續性之磷吸附試驗與釋放鐵量試驗(Nguyen et al., 2015) 52 七、 DPCS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5之動物降血磷試驗 53 (一) DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5倍量合成 53 1. DCPS 0.1325 N-Ac 1:2 1h之倍量合成(Lu, et al., 2004) 53 2. DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5之倍量合成(陳姿丹, 2008) 53 3. DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5之倍量合成(Aiedeh, et al., 2001) 54 (二) 動物降血磷試驗 54 (三) 血磷、血鈣和血鐵之測驗 57 八、 細胞存活率試驗 60 九、 統計分析 62 第五章 實驗結果 63 一、 不同去乙醯化度的去聚合幾丁聚醣之合成 63 (一) 去乙醯去聚合幾丁聚醣DADPCS合成 63 1. DACS合成(Kurita, 2001) 63 (1) 膠體滲透層析(GPC) 63 (2) 紅外線分光光譜(ATR) 64 (3) 核磁共振光譜儀(NMR) 65 2. DADPCS合成(Mao et al., 2004) 67 (1) 膠體滲透層析(GPC) 67 (2) 核磁共振光譜儀(NMR) 69 (3) 水溶性測試(Kubota et al., 2000) 71 (二) 去聚合幾丁聚醣DPCS之合成(Mao, et al., 2004) 73 1. 膠體滲透層析(GPC) 73 2. 核磁共振光譜儀(NMR) 75 3. 水溶性測試(Kubota, et al., 2000) 77 (三) 去聚合乙醯化幾丁聚醣DPCS N-Ac之合成(Lu et al., 2004) 79 1. 核磁共振光譜儀(NMR)-檢測去乙醯化度(DD%) 79 2. 水溶性測試 (Kubota, 2000) 84 3. 膠體滲透層析(GPC) 88 二、 不同去乙醯化度去聚合幾丁聚醣之檸檬酸接枝反應- DADPCS CA、DPCS CA和DPCS N-Ac CA之合成 (陳姿丹, 2008) 89 (一) 核磁共振光譜儀(NMR)-檸檬酸接枝率(CA%) 89 (二) 尋找較高檸檬酸接枝率(CA%)之反應條件 91 1. 反應時間 91 2. EDC或NHS(莫耳數)/CA(當量數)之比例 94 3. CA (當量數) /NH2 (莫耳數)之比例 99 (三) 去乙醯化度(DD%)和檸檬酸接枝率(CA%)之關係 104 (四) 水溶性試驗 (Kubota, 2000) 107 1. DADPCS系列 107 2. DPCS系列 108 (1) DPCS 0.1325 108 (2) DPCS 0.0828 109 (五) 膠體滲透層析(GPC)-確認檸檬酸接枝產物分子量和接枝的方式 111 (六) 紅外線分光光譜(ATR) 114 (七) 等電點滴定試驗(Salgin et al., 2013) 120 三、 鐵接枝-接枝型檸檬酸基-不同去乙醯化度去聚合幾丁聚醣- DADPCS CA Fe、DPCS CA Fe和DPCS N-Ac CA Fe之合成 121 (一) 含鐵量試驗之檢量線 (Aiedeh et al., 2001) 121 (二) 鐵接枝反應 (Aiedeh et al., 2001, Burger et al., 2001) 122 1. Fe(莫耳數)/CS monomer(莫耳數)之反應比例 122 2. 檸檬酸基對樣品接枝鐵的影響 123 3. 檸檬酸接枝鐵之能力 125 (三) 膠體滲透層析(GPC) 128 (四) 紅外線光譜圖(ATR) 130 (五) 水溶性試驗 (Kubota, 2000) 137 (六) 示差掃描熱分析儀(DSC) 138 四、 CS CA Fe、DADPCS CA Fe、DPCS CA Fe和DPCS N-Ac CA Fe之磷吸附試驗 140 (一) 含磷量試驗檢量線((Chen et al., 1956) modified by Dunham et al., 2005) 140 (二) 磷吸附試驗 142 1. pH 1.0磷吸附試驗(Burger et al., 2001) 142 2. pH 4.5、7.5之磷吸附試驗(Burger, et al., 2001) 148 (三) 在pH 1.0、4.5、7.5樣品釋放鐵的量 149 (四) 模擬胃腸道從pH 1.0、4.5至7.5連續性變化之磷吸附試驗(Nguyen et al., 2015) 152 1. pH 1.0、4.5至7.5連續性變化之樣品吸附磷的量 152 2. pH 1.0、4.5至7.5連續性變化之樣品釋放鐵的量 154 五、 DPCS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5之動物降血磷試驗 157 (一) DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5倍量合成 157 1. DCPS 0.1325 N-Ac 1:2 1h倍量合成(Lu et al., 2004) 157 2. DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5倍量合成(陳姿丹, 2008) 158 3. DCPS 0.1325 N-Ac 1:2 1h CA 1:5:5:5 Fe 1:5倍量合成(Aiedeh et al., 2001) 160 (二) 動物降血磷試驗 160 六、 細胞存活率試驗 166 第六章 結論 168 第七章 參考資料 173 | |
dc.language.iso | zh-TW | |
dc.title | 含鐵檸檬酸接枝型幾丁聚醣應用於口服降血磷之研究 | zh_TW |
dc.title | Study of Iron-Based Citric Acid Conjugated Chitosan as an Oral Phosphate Binder | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鍾次文,楊智強 | |
dc.subject.keyword | 慢性腎臟衰竭,高血磷,降血磷藥物,幾丁聚醣,檸檬酸,鐵, | zh_TW |
dc.subject.keyword | chronic kidney disease,hyperphosphatemia,phosphate binders,chitosan,citric acid,iron, | en |
dc.relation.page | 182 | |
dc.identifier.doi | 10.6342/NTU201603779 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-11-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 6.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。